Overview
Aequita Bioworks uses artificial intelligence and machine learning to speed up drug discovery by analyzing complex biological data with a computational platform. This in silico approach moves tasks that used to require months in the lab into data-center simulations. The company develops its own drug candidates and may partner with pharmaceutical companies to apply its platform to their pipelines. Its initial focus targets muscle loss linked to GLP-1 medications, using simulations to model biological systems and offload significant laboratory work to the silicon platform. Revenue is expected from progressing proprietary drug candidates through clinical stages or through licensing and collaboration agreements with other life sciences players. Overall, the goal is to shorten development timelines and reduce costs in the biopharma discovery process while building a pipeline of drug candidates and/or deepening partnerships that leverage its AI-driven platform.
Work here?Claim your company
Simplify's Take
What believers are saying
- Aequita says its rapid sterility platform cuts release-testing time to about 20 hours.
- April 2026 reporting said Sapho Bio raised $5 million from Mochi Health and angels.
- The company remains active in California, preserving optionality for fundraising and partnerships.
What critics are saying
- The company has no posted pipeline data on Patsnap as of May 2026.
- Aequita’s identity is unstable, with website branding shifting to Sapho Bio by 2026.
- No SEC filings, clinical trials, or published partnerships support a credible commercialization timeline.
What makes Aequita Bioworks unique
- Aequita’s website now redirects to Sapho Bio, suggesting a rapid pivot from original branding.
- It pairs RNA-based qPCR sterility testing with standard lab workflows and fast turnaround.
- Its pipeline still lists a muscle-sparing biologic for GLP-1-linked muscle loss.
Help us improve and share your feedback! Did you find this helpful?